ACM reports its Q3 fiscal 2026 results on August 11 with a notable insider endorsement at the current price level — a signal that stands out against a backdrop of persistent analyst target cuts and a stock trading nearly 21% below its year-to-date high.
The insider story is the most compelling setup heading into the print. CEO Troy Rudd bought roughly $300,000 worth of shares at $71.02 in May, the CFO Gaurav Kapoor added $101,000 at a similar price, and President Lara Poloni followed with another $298,000 purchase in June at $70.63. All three bought within a week of the prior quarter's earnings reaction — a report that sent the stock down 11–13% in a single session and a further 10–11% over the following five days. That cluster of C-suite buying, totalling nearly $700,000 in net open-market purchases over 90 days, reads less like routine participation and more like a deliberate signal at a price the insiders consider dislocated.
The broader positioning picture is measured rather than alarmed. Short interest at 5.9% of the free float is a meaningful level, but it has fallen sharply — down nearly 9% over the past week — suggesting bears have been trimming ahead of the report rather than pressing new positions. Borrow availability is extremely loose, with over 127 million shares available relative to the roughly 7.8 million on loan, so there is no squeeze dynamic in play. Options positioning has drifted slightly more defensive in recent sessions, with the put/call ratio at 0.79 — near its 52-week high of 0.81 — but the z-score of 0.78 keeps this well within one standard deviation of normal. The stock has fallen 3.3% in the past session and 2% on the week to $73.30, recouping some of a 7.4% monthly gain before Monday's sell-off.
The analyst debate has one consistent theme: everyone still rates the stock positively, but targets have been coming down steadily since the last earnings miss. RBC Capital cut its target from $111 to $105 in late July while holding its Outperform. Truist and Citigroup have both trimmed their numbers multiple times since May, and the consensus mean now sits around $99 — a 35% premium to the current price. Bulls point to a record backlog, steady organic growth, free cash flow generation, and a capital-return commitment that drives a high dividend factor score at the 91st percentile. Bears flag that AI investment is compressing margins, that the last two prints produced double-digit negative reactions, and that near-term free cash flow was held back by delayed claims resolutions. The earnings yield factor has been slipping over the past month, consistent with the idea that the market is pencilling in pressure rather than a rebound.
The print will test whether the C-suite conviction — expressed in open-market buying at prices close to today's level — is vindicated by a margin trajectory and backlog conversion that finally breaks the pattern of the past two quarters.
See the live data behind this article on ORTEX.
Open ACM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
